Online Weight-Loss Programs: Eligibility, Costs and Follow-Up

A telehealth GLP-1 program provides medical weight-management services remotely through a secure online platform. Depending on the program and what is medically appropriate, treatment options may include medications containing semaglutide, tirzepatide, or another prescription weight-management medication.

Compounded semaglutide injections start at $99/mo and compounded tirzepatide injections start at $149/mo, with the plan commitments shown below.

Current GLP users can access the same injection starting rates with a six-month plan: compounded semaglutide $99/mo ($594 upfront); compounded tirzepatide $149/mo ($894 upfront). Pay upfront or use Affirm, Klarna or Afterpay to split the payments, subject to eligibility and approval. Other billing options and oral current-user prices are listed on the pricing page. Treatment requires provider approval.

Luma’s published plans include medication if prescribed, licensed-provider oversight, necessary supplies and shipping, with no membership fee. Prices do not change by dose. Medical care is provided by Arora Health and Aesthetics; Luma connects patients with that care.

• Your treatment history and current medications: these help the provider assess eligibility and patient tier.
• The plan length, total due upfront and next billing date—not just the monthly equivalent. You can use Affirm, Klarna or Afterpay to split the payments, subject to eligibility and approval.
• The dispensing pharmacy and how to contact the clinical team for follow-up.

Can I split a prepaid Luma bill?

An intake submission does not guarantee a prescription. Cancel upcoming orders anytime before your next billing date through your patient portal or by emailing support@joinluma.com. That is separate from a refund for an already-billed order. Read the Terms of Service.

In practical terms, medically guided treatment means a qualified, licensed healthcare provider evaluates whether prescription treatment is appropriate and oversees the patient's care. Depending on state law and the platform, care may be provided by a licensed physician or another qualified licensed prescriber, such as a nurse practitioner or physician assistant.

The provider may review:

• Height, weight, and BMI
• Medical and surgical history
• Current medications and allergies
• Previous weight-loss treatments
• Weight-related medical conditions
• Treatment goals and potential contraindications

This information helps the provider determine whether a GLP-1-based treatment may be appropriate for that individual.

Most telehealth programs begin with an online medical questionnaire. Patients may be asked about current weight and height, weight history, health conditions, prescriptions, previous surgeries, allergies, pregnancy status when relevant, previous GLP-1 use, and current symptoms.

Patients should answer accurately. Information that may seem unrelated to weight loss can still influence whether a medication is appropriate.

Submitting a questionnaire is not the same as automatically receiving a prescription. A licensed healthcare provider should review the patient's information and decide whether treatment is medically appropriate.

• Approve treatment when appropriate
• Request additional information
• Recommend a different treatment
• Request laboratory testing or further evaluation when appropriate
• Determine that prescription treatment is not appropriate

A legitimate prescription program should not guarantee medication before a clinical evaluation occurs.

Eligibility is more than a BMI number

Weight, height and weight-related conditions are part of the assessment, but they are not an automatic prescription approval. The provider also needs your medication list, allergies, previous GLP-1 treatment, relevant medical history and pregnancy plans when applicable. Approval criteria and warnings belong to the specific medication being considered; a compounded product does not acquire an FDA-approved drug’s indication simply because it contains semaglutide or tirzepatide.

Read our GLP-1 eligibility guide for more context, then share your actual history rather than selecting answers just to meet a threshold.

Are labs always required before prescribing?

Not every evaluation has the same testing needs. The provider may request laboratory testing, recent medical records or an in-person assessment if your history or symptoms require it. This article does not establish a universal no-lab pathway or promise that external tests are included in a plan price. Ask whether tests are needed for you, where to obtain them and what any separate cost would be before proceeding.

What if I am switching from another program?

Provide the medication name, formulation, concentration if supplied in a vial, current prescribed dose, last dose date and side effects. A photo of the prescription label can help the team clarify what you received. A syringe measurement in “units” alone does not identify a dose. Do not overlap prescriptions or restart at a previous dose without the clinician’s instructions.

Not always.

Depending on the patient's circumstances and applicable state requirements, an evaluation may involve a secure medical questionnaire, messaging, a phone consultation, or a video visit. An asynchronous evaluation may be appropriate in some situations, while others require additional communication or a synchronous visit.

The important part is that an actual licensed healthcare provider evaluates the patient rather than a prescription being generated automatically from a checkout form.

If treatment is appropriate, the provider can determine which available option may best fit the patient. Semaglutide and tirzepatide are commonly discussed, but they are not identical medications.

Both can reduce appetite and food intake. The most appropriate option is not necessarily the same for every patient.

GLP-1 medications are generally started at lower doses and increased gradually according to the treatment plan. This process is called titration.

Starting low and escalating gradually can help the body adjust. Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort can be harder to tolerate when treatment is increased too quickly.

Why dosing guidance matters

Dosing instructions are especially important when medication is dispensed in a multidose vial. A prescribed dose in milligrams and the units marked on a syringe are not interchangeable measurements. The number of syringe units depends on the medication's concentration.

After a prescription is issued, medication is dispensed by a pharmacy authorized to fill it. Depending on the prescription, a patient may receive a commercially manufactured medication or a compounded medication when legally permitted and medically appropriate.

Patients should know what they are receiving. The label should identify the drug, strength or concentration when applicable, patient directions, dispensing pharmacy, and storage instructions.

Ask for the dispensing pharmacy’s name and contact information before using the medication. The FDA’s unapproved GLP-1 guidance recommends obtaining a prescription through a doctor and filling it at a state-licensed pharmacy; check the pharmacy through the relevant state board. A website seal or attractive checkout is not a substitute for those checks.

Compounded medications are different from FDA-approved commercial products such as Wegovy or Zepbound. Compounded drugs are not FDA-approved, and the FDA does not review their safety, effectiveness, or quality before they reach patients.

Qualified compounding pharmacies may prepare medications under specific federal and state requirements when legally permitted and medically appropriate. A compounded medication should not be described as generic, bioequivalent to, or interchangeable with an FDA-approved product.

Patients should be told:

• What medication they are receiving
• Its strength or concentration
• Exactly how much to administer
• Which U.S. licensed pharmacy dispensed it
• How it should be stored
• How to reach the prescribing team or pharmacy with questions

Many telehealth programs arrange for the dispensing pharmacy to ship medication directly to the patient's home. Depending on the treatment, the package may include medication, administration supplies, alcohol pads, dosing directions, and storage information.

Provider review, pharmacy processing and delivery are separate stages. Requests for additional information can delay review; dispensing follows an issued prescription. Any shipping estimate is not a promise of approval or an arrival date. Review the shipment when it arrives and follow the pharmacy's storage instructions. Ask about damaged packaging, temperature exposure, missing supplies, or unexpected medication appearance before use.

The first shipment should not be the end of medical care. During treatment, the care team may monitor weight changes, appetite, side effects, medication tolerance, dose progression, adherence, nutrition, changes in health, and new medications.

What should follow-up look like?

Follow-up may happen through secure messaging, online check-ins, phone calls, video visits, or questionnaires. What matters is that patients have a clear way to reach the clinical team when questions or problems arise.

Common side effects of GLP-1-based medications are gastrointestinal and can include nausea, constipation, diarrhea, vomiting, abdominal discomfort, indigestion, and reduced appetite. Symptoms may be more noticeable when treatment begins or the dose increases.

A healthcare provider can help determine whether symptoms may be managed conservatively, whether dose escalation should be reconsidered, or whether further evaluation is needed. The goal is not to make someone so nauseated that they cannot eat; treatment should remain tolerable while supporting appropriate nutrition and hydration.

Routine questions about symptoms, dosing and refills belong with the prescribing clinical team; billing and delivery questions can be directed to Luma support. Customer support is not a substitute for medical assessment. If a symptom is severe or you believe you are having a medical emergency, seek urgent medical care rather than waiting for an online reply.

Before a refill, report side effects, treatment gaps, new medications and relevant health changes. The provider may need more information before continuing or changing treatment. Confirm the next clinical check-in and refill process with the team; paying for a plan does not authorize you to increase your dose.

Medication can reduce appetite considerably, making adequate nutrition more important—not less. Patients still need protein, fluids, fiber, vitamins, minerals, essential fats, and other nutrients.

Significant weight loss can include some lean tissue. Adequate protein, resistance training, regular activity, and avoiding unnecessarily severe calorie restriction can help support muscle and physical function.

Weight loss is rarely linear. Faster initial loss may be followed by a slower period, weeks with little change, and eventually a plateau. That does not automatically mean the medication stopped working.

As body weight decreases, energy requirements generally decrease too. A good telehealth program should help patients understand these changes rather than treating every plateau as an automatic reason to increase the dose.

Should every patient reach the highest dose?

No. Higher is not automatically better.

• Treatment response and appetite
• Side effects and tolerability
• Current dose and time at that dose
• Treatment goals
• The prescribing provider's guidance

Some patients may progress according to the medication's schedule; others may need a different approach. Patients should not change their medication independently.

These details matter just as much as the advertised monthly price.

Patients should be cautious when a program:

• Guarantees a prescription before medical review
• Does not clearly involve a licensed healthcare provider
• Will not identify what medication is being prescribed
• Provides unclear dosing instructions
• Makes unrealistic weight-loss guarantees
• Has no clear way to contact the care team
• Makes pricing or recurring billing difficult to understand

Convenience should not require sacrificing transparency.

Telehealth itself does not determine whether treatment is appropriate or safe. What matters is the quality of care behind the platform.

• Appropriate patient screening
• Qualified licensed healthcare providers
• Legitimate prescription processing
• Appropriate pharmacy dispensing
• Clear dosing and side-effect education
• Ongoing access to clinical support

Patients also play an important role by providing accurate medical information and communicating health changes throughout treatment.

A telehealth GLP-1 program should be more than “order medication and wait for a package.” A medically guided program should follow a clear care pathway.

The convenience of telehealth can make weight-management care easier to access, but clinical oversight remains important. Patients should know what they are receiving, understand how to use it, know where it was dispensed, and have a clear way to contact their care team.

At Luma, eligible patients can complete an online medical evaluation reviewed by a licensed healthcare provider. When treatment is medically appropriate and prescribed, patients receive dosing guidance and ongoing support throughout their weight-management journey.